Clinical trials: Precancerous Conditions
Actinic Keratoses
Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial
Transient local skin reactions with topical Actinic Keratosis treatments such as 5-FluoroUracil (5-FU) often lead to non-adhesion from patients and thus to treatment failure.
- Trial name
- NCT04875026
- Testing
- 5-fluorouracil 4% (Tolak), Dexeryl
- Where
- 27 sites in France, Germany and 2 more
- Volunteers
- 146 people
- Sponsor
- Pierre Fabre Medicament
Cervical Intraepithelial Neoplasia
Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)
The purpose of this study is to access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 2, 2/3 or 3 (CIN3)
- Trial name
- NCT02596243
- Testing
- GX-188E
- Where
- 16 sites in Estonia, South Korea and 1 more
- Volunteers
- 134 people
- Sponsor
- Genexine, Inc.
Barrett Esophagus, Esophageal Adenocarcinoma
Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay on cells collected using the EsoCheck 510(k) cleared device, to detect Barrett's Esophagus, with and without dysplasia, and/or…
- Conditions
- Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
- Trial name
- ESOGUARDBE1 (NCT04293458)
- Testing
- EsoGuard
- Where
- 27 sites in United States, Spain
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Lucid Diagnostics, Inc.
Actinic Keratosis
A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies
This study is designed to follow up patients who have achieved complete clearance of AK lesions at the Day 57 visit having completed the PEP005-016 or PEP005-025 studies over a 12 month period to assess both recurrence of Actinic…
- Trial name
- NCT00953732
- Testing
- Lesion count
- Where
- 42 sites in United States, Australia
- Volunteers
- 117 people
- Sponsor
- Peplin
Actinic Keratosis
Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
The objective of the trial is to investigate the Safety of LEO 43204 0.018%, 0.037% and 0.1% for actinic keratosis applied once daily for three consecutive days on face/chest, scalp and trunk/extremities, respectively.
- Trial name
- NCT02305888
- Testing
- LEO 43204
- Where
- United States
- Volunteers
- 189 people
- Sponsor
- LEO Pharma
Actinic Keratoses
An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses
This study is being undertaken to: 1. assess the safety of fluorouracil cream for the treatment of actinic keratoses ("AKs") on other common skin surface areas (e.g., posterior scalp, ears, neck, lips, arms and hands); 2.
- Trial name
- NCT00377273
- Testing
- fluorouracil cream 0.5%
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi
Barrett's Esophagus, High Grade Dysplasia
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
The purpose of this study is to evaluate the safety and effectiveness of the CryoSpray Ablation System to treat esophageal low grade dysplasia (LGD) or high grade dysplasia (HGD) within Barrett's Esophagus (BE).
- Conditions
- Barrett's Esophagus, High Grade Dysplasia, Low Grade Dysplasia
- Trial name
- ICE (NCT00526786)
- Testing
- CryoSpray Ablation System (510(k) NO: K070893)
- Where
- 16 sites in United States
- Volunteers
- 78 people
- Sponsor
- CSA Medical, Inc.
Precancerous Conditions, Carcinoma
Identification of a Plasma Proteomic Signature for Lung Cancer
The primary objective is to identify a panel of plasma and/or serum proteins that differentiates the absence or presence of lung malignancy in samples obtained from subjects enrolled in this IRB/EC approved study with pulmonary…
- Trial name
- NCT01752101
- Where
- 12 sites in United States
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Integrated Diagnostics
Actinic Keratosis
A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis
This was a placebo controlled, double blind, randomized phase II dose-response study to evaluate the efficacy and safety of BF-200 ALA (containing the active ingredient 5 - aminolevulinic acid- ALA) used with photodynamic therapy…
- Trial name
- NCT02799030
- Testing
- BF-200 ALA 1%, BF-200 ALA 3%, BF-200 ALA 10%
- Volunteers
- 105 people
- Sponsor
- Biofrontera Bioscience GmbH
Actinic Keratosis (AK)
An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face
The research study will evaluate how the body absorbs and reacts to reformulated Levulan Kerastick when applied to actinic keratosis lesions (AKs) on the skin of the forearms or face followed by photodynamic therapy (PDT), a…
- Trial name
- NCT07729579
- Testing
- Investigational drug, Photodynamic therapy
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Cervical Intraepithelial Neoplasia 3
Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
This study is to follow up on the change of immune response by measuring HPV type 16/18 E6 and E7 specific T cell response and lesion condition in subjects who have administered in DNA-based therapeutic vaccine.
- Trial name
- GX-188E (NCT02411019)
- Testing
- GX-188E
- Where
- South Korea
- Volunteers
- 67 people
- Sponsor
- Genexine, Inc.
Actinic Keratosis
Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery
The objective of this study is to evaluate the efficacy and safety of imiquimod cream versus placebo cream when used after cryosurgery in the treatment of actinic keratoses (AKs).
- Trial name
- NCT00894647
- Testing
- imiquimod cream
- Where
- 18 sites in United States, Canada
- Volunteers
- 247 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Healthy, Actinic Keratosis
PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects
The purpose of this phase 1 trial is to investigate the local tolerability on the finger following exposure to PEP005 Gel 0.015% or 0.05% and hand washing once daily, for 2 or 3 consecutive days.
- Trial name
- NCT01302925
- Testing
- PEP005 Gel
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peplin
Gastro-Intestinal Disorder, Barrett Esophagus
Clinical Utility Evidence for TissueCypher®
Cernostics has developed a new diagnostic test, and this study will measure how gastroenterologists and foregut surgeons make diagnostic and treatment decisions when presented with different information in the context of…
- Trial name
- NCT05200325
- Testing
- Educational materials for TissueCypher
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Qure Healthcare, LLC
CIN - Cervical Intraepithelial Neoplasia, CIN 1
A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV.
The goal of this clinical trial is to investigate the safety and efficacy of Papillex® on the regression of abnormal cervical cells caused by HPV in women with a cervical intraepithelial neoplasia (CIN) 1 or 2 diagnosis.
- Conditions
- CIN - Cervical Intraepithelial Neoplasia, CIN 1, CIN 2, HPV
- Trial name
- NCT06979180
- Testing
- Papillex®
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Papillex Inc.
Keratosis, Actinic
Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick
The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving…
- Trial name
- NCT02281136
- Testing
- Aminolevulinic Acid (ALA), BLU-U
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Barrett's Esophagus, High-grade Dysplasia in Barrett Esophagus
Eradicating Barrett's Esophagus Using Radiofrequency Ablation or a Novel Hybrid Argon Plasma Coagulation Technique
Lay summary: Barrett's Esophagus (BE) involves a change of the esophagus lining (BE epithelium) which in a small proportion of patients could be the starting point for the development of cancer (esophageal adenocarcinoma).
- Conditions
- Barrett's Esophagus, High-grade Dysplasia in Barrett Esophagus, Low Grade Dysplasia in Barrett Esophagus
- Trial name
- BURN (NCT03621319)
- Testing
- Hybrid argon plasma ablation (HAPC), Radiofrequency ablation (RFA)
- Where
- 13 sites in United States
- Volunteers
- 41 people
- Sponsor
- Erbe Elektromedizin GmbH
Cervical Cancer, Cervical Intraepithelial Neoplasia II
Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer
The purpose of this study is to determine whether Insulin-like Growth Factor II is elevated sufficiently to detect Cervical Intraepithelial Neoplasia II (CIN II), Cervical Intraepithelial Neoplasia III (CIN III), and cervical…
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia II, Cervical Intraepithelial Neoplasia III
- Trial name
- NCT01371695
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Onconix, Inc
Ulcerative Colitis, Crohn Disease
Systems Biology of Gastrointestinal and Related Diseases
This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and…
- Conditions
- Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp
- Trial name
- NCT05579444
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Viome
Actinic Keratosis
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
Part 1: To identify Maximum Tolerated Dose (MTD) levels of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate the efficacy of LEO 43204 in two doses after once daily treatment for two consecutive…
- Trial name
- NCT02120456
- Testing
- LEO 43204
- Where
- 21 sites in United States, Canada
- Volunteers
- 224 people
- Sponsor
- LEO Pharma